Mostrar el registro sencillo del ítem

dc.contributor.authorÁlvarez-Heredia, Pablo
dc.contributor.authorReina-Alfonso, Irene
dc.contributor.authorDomínguez-del-Castillo, José Joaquín
dc.contributor.authorHassouneh, Fakhri
dc.contributor.authorGutiérrez-González, Carmen
dc.contributor.authorBatista-Duharte, Alexander
dc.contributor.authorPérez, Ana Belén
dc.contributor.authorSarramea, Fernando
dc.contributor.authorJaén Moreno, María José
dc.contributor.authorCamacho-Rodríguez, Cristina
dc.contributor.authorTarazona, Raquel
dc.date.accessioned2024-01-15T13:28:13Z
dc.date.available2024-01-15T13:28:13Z
dc.date.issued2024
dc.identifier.issn1999-4915
dc.identifier.urihttp://hdl.handle.net/10396/26556
dc.description.abstractHuman cytomegalovirus (HCMV) is linked to age-related diseases like cardiovascular disease, neurodegenerative conditions, and cancer. It can also cause congenital defects and severe illness in immunocompromised individuals. Accurate HCMV seroprevalence assessment is essential for public health planning and identifying at-risk individuals. This is the first HCMV seroprevalence study conducted in the general Spanish adult population in 30 years. We studied HCMV seroprevalence and HCMV IgG antibody titres in healthy adult donors (HDs) and HCMV-related disease patients from 2010 to 2013 and 2020 to 2023, categorized by sex and age. We compared our data with 1993 and 1999 studies in Spain. The current HCMV seroprevalence among HDs in Spain is 73.48%. In women of childbearing age, HCMV seroprevalence has increased 1.4-fold in the last decade. HCMV-seropositive individuals comprise 89.83% of CVD patients, 69% of SMI patients, and 70.37% of COVID-19 patients. No differences in HCMV seroprevalence or HCMV IgG antibody titres were observed between patients and HDs. A significant reduction in Spanish HCMV seroprevalence among HDs was observed in 1993. However, women of childbearing age have shown an upturn in the last decade that may denote a health risk in newborns and a change in HCMV seroprevalence trends.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightshttps://creativecommons.org/licenses/by/4.0/es_ES
dc.sourceViruses, 16 (1), 6 (2024)es_ES
dc.subjectHCMVes_ES
dc.subjectSeroprevalencees_ES
dc.subjectSpaines_ES
dc.subjectInflammationes_ES
dc.titleSpanish HCMV Seroprevalence in the 21st Centuryes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.3390/v16010006es_ES
dc.relation.projectIDUnión Europea. Grant PE-COVID-0053–2020es_ES
dc.relation.projectIDJunta de Andalucía. FEDER Andalucía 2014–2020es_ES
dc.relation.projectIDJunta de Andalucía. Grant PI-0324–2018es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem